Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine for Depression and PTSD in Veterans with TBI
NCT06228391Phase 2Not yet recruiting
- Start
- Mar 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ketamine in major depressive disorder (MDD) and post-traumatic stress disorder (PTSD) (2 arms). Primary endpoint: Change in Severity of Depressive Symptoms at 3 weeks. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT06228391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06228391.